The state of New Jersey currently has 424 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
NCT06173505
Recruiting
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: New Jersey Center for Cancer Research, Brick, New Jersey
Conditions: Nonsquamous Non-small Cell Lung Cancer
Register for Updates
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT05736367
Recruiting
To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Breast Cancer
Register for Updates
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT06518837
Recruiting
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey +6 locations
Conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Register for Updates
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
NCT05351294
Recruiting
To determine if the experimental approach of early radiation oncology involvement alongside standard oncologic care will result in higher HRQL at 6 months compared to the control arm receiving standard oncologic care alone, based on the global subscale score of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: RWJBarnabas Health Jersey City Medical Center, Jersey City, New Jersey +5 locations
Conditions: Radiation Therapy, Metastatic Cancer
Register for Updates
Support for Cancer Patients Awaiting News
NCT06199570
Recruiting
This is a behavioral trial study to pilot test a stress management intervention for people with cancer who are undergoing routine cancer scans. The study will involve two pilot testing phases. Initial feasibility will be determined in an Open Trial phase, to inform any needed revisions to the intervention and/or protocol prior to a Pilot Randomized Controlled Trial phase. The Open Trial phase is an unblinded, single-site, single-arm open trial (n=10). The Pilot randomized clinical trial (RCT) ph... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Amanda Khoudary, Hackensack, New Jersey
Conditions: Lung Cancer
Register for Updates
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Center for Cancer Research, Brick, New Jersey
Conditions: Non Small Cell Lung Cancer
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Conditions: Myocarditis Acute, Cancer
Register for Updates
A Study of Sotorasib in People with Non-Small Cell Lung Cancer
NCT06582771
Recruiting
The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Non Small Lung Cancer
Register for Updates
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Rutgers Cancer Institute of New Jersey - 1614, New Brunswick, New Jersey
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Reducing Urban Cervical Cancer Disparities
NCT06416150
Recruiting
This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention. HERS aims to increase patient follow-up after abnormal test results through text message-based barriers counseling for women and supplemental telephone-based Health Coaching for women who miss their appointment.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
10/23/2024
Locations: Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Conditions: Cervical Cancer, Papilloma Viral Infection
Register for Updates
Kidney Cancer DNA Registry
NCT02087852
Recruiting
This registry will help us develop better methods of: * Preventing these cancers * Diagnosing these cancers * Treating these cancers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up), Basking Ridge, New Jersey +2 locations
Conditions: Renal Cancer
Register for Updates
Ribociclib and Bicalutamide in AR+ TNBC
NCT03090165
Recruiting
This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Triple Negative Breast Cancer
Register for Updates